Advertisement
Used as a way to measure normal biological processes in the body, pathological processes, or the response of the body to a therapeutic intervention, Biomarkers have become an essential part of clinical development because they potentially offer a faster route to market versus the conventional drug development approach, where success rates have steadily declined in recent years. Attrition rates for drugs in discovery and development are currently very high with less than 10% of tested products entering phase I trials. With increasing costs involved in the drug development process, and growing concern that fewer drugs are making it through to the marketplace each year, the pharmaceutical industry is embracing biomarkers as a way of predicting a drug candidate's performance early and with a greater degree of certainty.
Advertisement
"The FDA, as well as academic and research organizations, have recognized Biomarkers as having great potential to speed the development and approval of medical products," said Wendy Hamilton, vice president of product strategy and marketing, Scientific business of Thomson Reuters. "Because biomarkers can predict drug efficacy and safety more quickly than conventional clinical endpoints, they hold the potential to substantially accelerate product development, and because they help to identify earlier those drug candidates that are likely to fail, they reduce drug development costs. In addition, biomarkers could revolutionize therapeutic treatments in areas such as oncology, with their capacity to tailor therapies to specific individuals."
"Biomarkers such as Her2 have already shown their effectiveness and benefit in clinical trials," said Colin Williams, product manager, biology & bioinformatics, Scientific business of Thomson Reuters. "Many other biomarkers are following suit in clinical research but selecting the correct biomarker can be a real challenge. Identifying the correct biomarker in clinical studies can mean the difference between a drug candidate being approved or not, which has profound implications for both the patients awaiting treatment and the financial security of the drug company involved."
Thomson Reuters has expanded the availability of BIOMARKERcenter, its unique comprehensive resource for biomarker intelligence. BIOMARKERcenter is now available through several delivery options: as a subscription option to users of Prous Science Integrity(R), as an XML feed for in-house bioinformatics solutions and also as a standalone web application. This solution covers biomarkers identified in literature, patents, conferences, clinical trial information, and other sources for all major therapeutic areas and is the first to provide the pharmaceutical industry with a framework for assessing the potential of a biomarker. BIOMARKERcenter is the most comprehensive resource of its kind and continues to expand rapidly, with more than 2,000 different biomarkers, and 13,000 unique uses of these biomarkers within its database.
For further information about BIOMARKERcenter, please go to: http://scientific.thomsonreuters.com/products/biomarkercenter/
To read the full white paper, "Biomarkers: an indispensable addition to the drug development toolkit," please register online at: http://scientific.thomsonreuters.com/forms/biomarkers/
About Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. Thomson Reuters shares are listed on the New York Stock Exchange (NYSE: TRI); Toronto Stock Exchange (TSX: TRI); London Stock Exchange (LSE: TRIL); and Nasdaq (Nasdaq: TRIN). For more information, go to www.thomsonreuters.com.
SOURCE Thomson Reuters
